Nantbio, Inc.

Nant Holdingsip, LLC

Nantomics, LLC

Heather McFarlane

Kayvan R Niazi

Patrick Soon-Shiong

Shahrooz Rabizadeh

Oleksandr V Buzko

Paul Weingarten

Stephen Charles Benz

Clifford Anders Olson

Shiho Tanaka

Connie Tsai

Chunlin Tao

Justin Golovato

David T Ho

Hermes J Garban

Anna B Juncker-Jensen

Mark Guido

Tan Trinh

Helty Adisetiyo

Compositions and methods for NK cell based treatments, and particularly NK cells that express and intracellularly retain IL-2, are presented in which the NK cells are stimulated with a chimeric protein that has a cancer cell targeting portion and an IL-12 portion. Beneficially, such chimeric protein has substantially reduced systemic toxicity and induces IFN-γ secretion in a targeted manner. Moreover, chimeric proteins contemplated herein also significantly enhanced IFN-γ secretion in NK cells that express and intracellularly retain IL-2 as compared to native NK cells. Preferred chimeric proteins comprise SEQ ID NO:1 or SEQ ID NO:2, and SEQ ID NO:3.

Targeted IL-12 treatments and methods to stimulate haNK and NK92mi cells

Antibodies, fragments thereof, and chimeric proteins comprising same are presented that have specific binding activity against CD30. Advantageously, contemplated molecules can be used in pharmaceutical compositions for immune therapy, particularly in individuals diagnosed with hematopoietic malignancies, including Hodgkin lymphoma, CD30-positive B cell lymphomas, CD30-positive T cell lymphomas, CD30-positive NK cell lymphomas.

Anti-CD30 monoclonal antibodies and chimeric antigen receptors

Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.

Compositions and methods of Rit1 inhibition

Compounds and compositions are presented that inhibit K-ras, and especially mutant K-ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.

Compositions and methods of targeting mutant K-RAS

Growing community of inventors

Los Angeles, CA, United States of America

Heather McFarlane